Senolytics
Senolytics are compounds intended to clear senescent cells. Fisetin plus quercetin has strong mouse and human-tissue rationale from Yousefzadeh 2018 but still has no published human F+Q efficacy trial; D+Q has small human pilots in IPF and diabetic kidney disease.
Senolytics scored 5.9 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Botanical Extract (non-adaptogenic).
What It Is
Senolytics are compounds designed to clear senescent cells: damaged, stress-adapted cells that stop dividing but refuse to die. In small amounts, senescence protects you from cancer and helps with wound healing. When senescent cells persist, they secrete SASP, an inflammatory mix of cytokines, proteases, and growth signals that can damage nearby tissue and spread dysfunction.
The common OTC version is F+Q: fisetin plus quercetin. The prescription research version is D+Q: dasatinib plus quercetin. The logic comes from senescent-cell anti-apoptotic pathways, especially BCL-2, BCL-xL, PI3K, and AKT. Zhu 2015 showed that senescent cells rely on these survival pathways. Zhu 2017 then identified fisetin as senolytic in selected cell types, and Yousefzadeh 2018 made fisetin the best-known supplement candidate by showing reduced senescence markers and extended health and lifespan in mice.
That last phrase matters: in mice. Human evidence is much thinner. D+Q has small early pilots in IPF and diabetic kidney disease, while F+Q specifically still has no published human senolytic efficacy trial. Newer studies sharpen the caution: Farr 2024 missed its primary endpoint overall in a D+Q bone trial, and Shimizu 2025 found no overall primary or secondary endpoint benefit for a different senolytic botanical. Senolytics are real enough to take seriously, but not proven enough to treat like a routine longevity vitamin.
Terminology
For clinical-trial context, see the Chaib 2022 senolytics translation review.
- SASP: Senescence-Associated Secretory Phenotype. The inflammatory cytokine, protease, and signaling mixture released by senescent cells.
- BCL-2 / BCL-xL: Anti-apoptotic proteins that help some senescent cells resist programmed cell death.
- PI3K / AKT: Cell survival signaling pathway often upregulated in senescent cells.
- F+Q: Fisetin + quercetin. The OTC supplement stack most biohackers mean when they say senolytics.
- D+Q: Dasatinib + quercetin. Prescription senolytic combination with stronger human pilot evidence and higher risk.
- SCAP: Senescent-cell anti-apoptotic pathway. Survival pathway senolytics try to disable.
- p16 / p21: Cyclin-dependent kinase inhibitors used as senescence biomarkers.
- SA-beta-gal: Senescence-associated beta-galactosidase. A common senescence marker in cells and immune-cell assays.
- GRAS: Generally Recognized As Safe. FDA food-ingredient safety designation for specified uses, not disease treatment approval.
- GRN 341: FDA GRAS notice number for quercetin in specified food uses.
- AFFIRM-LITE: Mayo Clinic fisetin frailty RCT, NCT03675724.
- IPF: Idiopathic Pulmonary Fibrosis. A progressive lung-scarring disease studied in the D+Q pilot.
- HSC: Hematopoietic Stem Cell. A blood-forming stem cell compartment affected by senescence in animal studies.
- CYP3A4: Liver cytochrome P450 enzyme inhibited by quercetin during the dosing window.
- DOAC: Direct Oral Anticoagulant, such as apixaban or rivaroxaban.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 3 routes and 5 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| oral | Fisetin capsule (standardized extract) | N/A (no FDA-approved senolytic indication) | 1,000-2,000 mg, roughly 20 mg/kg body weight, for 2 consecutive days |
| oral | Quercetin capsule | N/A (no FDA-approved senolytic indication) | 1,000-1,250 mg for 2 consecutive days |
| oral | Dasatinib + Quercetin (D+Q, Rx) | Dasatinib 100 mg + quercetin 1,250 mg in early clinical pilot protocols | 3 consecutive days monthly |
Protocols
F+Q quarterly hit-and-run Anecdotal
- Dose
- Fisetin 1-2g + quercetin 1-1.25g
- Frequency
- Quarterly (every 3 months)
- Duration
- Indefinite cycling if appropriate
Community standard. Two consecutive days. Nick's protocol when he uses it. Avoid around procedures, anticoagulants, and high-risk medication windows.
F+Q extended pulse Anecdotal
- Dose
- Fisetin 1-2g + quercetin 1-1.25g
- Frequency
- 3 consecutive days monthly
- Duration
- Indefinite cycling if appropriate
Modeled after D+Q monthly dosing. Higher exposure than quarterly F+Q with no published human efficacy proof for this specific OTC combination.
D+Q clinical (under supervision) Clinical
- Dose
- Dasatinib 100 mg + quercetin 1,250 mg
- Frequency
- 3 consecutive days monthly in early pilot protocols
- Duration
- Per clinical guidance
Used in small pilots including [Justice 2019](https://pmc.ncbi.nlm.nih.gov/articles/PMC6412088/) and [Hickson 2019](https://pmc.ncbi.nlm.nih.gov/articles/PMC6796530/). Requires prescription and medical monitoring.
Post-chemotherapy / radiation Anecdotal
- Dose
- F+Q quarterly dosing
- Frequency
- Quarterly
- Duration
- 6-12 months post-treatment only if oncology clears it
Emerging protocol for treatment-induced senescence. Do not self-prescribe around active cancer, immunotherapy, targeted therapy, surgery, or radiation without oncology review.
Biomarker-guided senolytic timing Anecdotal
- Dose
- F+Q or clinical senolytic strategy based on senescence-marker panel
- Frequency
- Per biomarker reading
- Duration
- Ongoing reassessment
Research-stage idea. p16 / p21, SA-beta-gal, SASP panels, and gerodiagnostics are not yet standardized for consumer decision-making.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
How this score is calculated →
Upside contribution: 2.79
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 2.5 | 0.625 | |
| Breadth of Benefits | 15% | 4.2 | 0.630 | |
| Evidence Quality | 25% | 1.8 | 0.450 | |
| Speed of Onset | 10% | 3.0 | 0.300 | |
| Durability | 10% | 3.0 | 0.300 | |
| Bioindividuality Upside | 15% | 3.2 | 0.480 | |
| Total | 2.785 |
Upside Rationale
Senolytics has its strongest upside when the reader wants longevity, healthspan, cellular senescence and can use the intervention in the studied context. Shimizu et al. 2025 gives the score a real evidence anchor, while Guan et al. 2024 helps define where the effect is narrower or broader. The practical value is not magic; it is a specific lever that can matter when age, disease context, drug interactions, and whether the protocol is supervised already point in the right direction. The upside is strongest when the mechanism, population, and outcome line up instead of borrowing confidence from neighboring claims. In practice, the intervention belongs in a stack only after higher-use basics are already stable.
Efficacy (2.5/5.0). The strongest F+Q-specific evidence remains preclinical. Yousefzadeh 2018 found fisetin was the most potent senotherapeutic among tested flavonoids, reduced senescence markers in mice and human adipose tissue explants, and extended mouse health and lifespan when given late in life. D+Q has more human signal: Justice 2019 reported feasibility and physical-function improvements in a 14-person IPF pilot, and Hickson 2019 reported senescence-marker movement in 14 people with diabetic kidney disease. But neither pilot proves clinical efficacy, and neither validates F+Q. Farr 2024 further tempers the class by missing its primary endpoint overall in postmenopausal women.
Breadth of Benefits (4.2/5.0). Senescence is a systemic aging mechanism, which is why the theoretical upside is wide. Senescent cells appear across adipose, vascular, immune, lung, kidney, brain, skin, bone, and stem-cell niches. Xu 2018 showed D+Q improved physical function and post-treatment survival in old mice. Chang 2016 supports stem-cell rejuvenation in mouse hematopoietic and muscle compartments with ABT263. The breadth score reflects class biology more than F+Q clinical proof. In practice, the best candidates are older adults or people with accelerated senescence burden, not healthy 25-year-olds chasing extra optimization.
Evidence Quality (1.8/5.0). Evidence quality is the bottleneck. There are strong mouse studies, mechanistic papers, and early human pilots, but no published human F+Q efficacy trial. Guan 2024 reviewed 83 dietary-ingredient senescence studies and found only 5 human studies, with human evidence limited and risk of bias largely unclear. Shimizu 2025 was the only n>=100 completed human RCT found in the audit window and was null overall, with only a male subgroup signal for a different botanical. No Cochrane review, FDA senolytic approval, USPSTF recommendation, NICE endorsement, or major IPF society guideline support was found in the audit.
Speed of Onset (3.0/5.0). The expected timeline is weeks, not hours. Hickson 2019 measured senescence-associated markers after D+Q over an 11-day post-dose window, which supports relatively fast biomarker movement for the class. Functional changes in small pilots appear over weeks. For F+Q, there is no verified human onset timeline. The community expectation is that SASP burden falls first, then tissue-level repair and subjective energy changes may follow over several weeks if the user had enough senescent-cell burden to matter.
Durability (3.0/5.0). The hit-and-run design is the main durability advantage. If a senolytic clears the right persistent cells, those exact cells do not return when the supplement clears from circulation. Reaccumulation still happens over time through normal aging, chronic disease, injury, obesity, and metabolic stress. Quarterly dosing is a practical guess borrowed from the biology and D+Q-style intermittent designs, not a proven F+Q maintenance schedule. This is more durable than daily anti-inflammatory supplements but less certain than a lifestyle adaptation you can maintain and measure.
Bioindividuality (3.2/5.0). Response should depend heavily on baseline senescent-cell burden. Older adults, post-chemotherapy patients, people with fibrosis, diabetes, obesity, chronic kidney disease, or chronic inflammation may have more to gain. Younger adults probably have less target burden and more theoretical downside, because senescence also helps suppress tumors and coordinate repair. Farr 2024 suggests baseline senescent-cell burden may predict response better than age alone. That makes future biomarker-guided senolytics more interesting than blind quarterly use.
Downside contribution: 1.93 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 1.5 | 0.450 | |
| Side Effect Profile | 15% | 1.3 | 0.195 | |
| Financial Cost | 5% | 1.3 | 0.065 | |
| Time/Effort Burden | 5% | 1.2 | 0.060 | |
| Opportunity Cost | 5% | 1.3 | 0.065 | |
| Dependency / Withdrawal | 15% | 1.0 | 0.150 | |
| Reversibility | 25% | 1.8 | 0.450 | |
| Total | 1.435 | |||
| Harm subtotal × 1.4 | 1.743 | |||
| Opportunity subtotal × 1.0 | 0.190 | |||
| Combined downside | 1.933 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.593 |
Downside Rationale
Senolytics still needs caution because the downside profile depends on age, disease context, drug interactions, and whether the protocol is supervised, not only on the headline benefit. Safety, cost, and effort scores sit at 1.5, 1.3, and 1.2 out of 5, which means the tradeoff changes by user type. Shimizu et al. 2025 supports the core benefit, but the same evidence base leaves gaps around long-term use, nonresponders, and people outside the studied population. The downside is not only adverse events; it is also cost, effort, sourcing quality, contraindications, and the chance of chasing the wrong lever. That makes screening and expectation-setting part of the intervention, not an optional afterthought.
Safety risk (1.5/5.0). F+Q is much safer than D+Q, but safety is not zero-risk. Fisetin and quercetin are supplements, and quercetin has FDA GRAS notice GRN 341 for specified food uses. The main issues are drug interactions, anticoagulant potentiation, perioperative timing, pregnancy, severe kidney or liver disease, and active cancer. Active cancer is the hardest caution because senescence can suppress tumor growth. D+Q is a different category: dasatinib is a prescription oncology drug with risks including myelosuppression, bleeding, fluid retention, cardiovascular toxicity, pulmonary arterial hypertension, QT prolongation, severe dermatologic reactions, tumor lysis syndrome, embryo-fetal toxicity, and hepatotoxicity.
Side effect profile (1.3/5.0). High-dose fisetin can cause mild GI discomfort, nausea, or loose stool. Quercetin at 1,000-1,250 mg is usually uneventful but can add headache, tingling, GI upset, or medication-interaction risk in sensitive users. The intermittent model keeps exposure low: two days per quarter is easier to tolerate than daily dosing. D+Q side effects should not be generalized to F+Q because dasatinib drives most pharmaceutical-grade risk.
Financial cost (1.3/5.0). F+Q is cheap by longevity standards. A quarterly cycle typically costs $30-55 depending on brand and dose, with annual cost around $120-220. There is no device, subscription, lab requirement, or clinical visit required for the OTC version, although medication review is wise. D+Q is more expensive and requires prescription oversight.
Time / effort burden (1.2/5.0). The protocol is almost frictionless: two days of capsules per quarter. The practical effort is not swallowing pills. It is reviewing drug interactions, avoiding the dosing window around procedures, timing with meals, and deciding whether you are old enough or high-burden enough for the mechanism to make sense. This is one of the lowest-effort interventions in the archive.
Opportunity cost (1.3/5.0). The opportunity cost is low because F+Q does not displace exercise, sleep, protein, creatine, sauna, or cardiometabolic work. The risk is psychological: using senolytics as a shortcut while ignoring the interventions that lower senescent-cell formation in the first place. If you are inflamed because you sleep five hours and never train, quarterly fisetin is not the bottleneck.
Dependency / withdrawal (1.0/5.0). There is no dependency model. Fisetin and quercetin are absent from the body for nearly all of the quarter, and there is no receptor withdrawal pattern. Stopping simply means you stop applying intermittent senolytic pressure. Any benefit fades as new senescent cells accumulate through normal biology.
Reversibility (1.8/5.0). Senescent-cell clearance is irreversible by design. If you clear the right persistent cells, that is the whole point. If you clear cells involved in tumor suppression, tissue repair, wound healing, pregnancy biology, or adaptive remodeling, stopping the supplement cannot bring those cells back. The probability of meaningful harm from OTC F+Q appears low, but reversibility is worse than most supplements because the intended target is cell death.
Verdict
Senolytics is a 5.9/10 fit for longevity, healthspan, cellular senescence, especially for readers who can match the protocol to age, disease context, drug interactions, and whether the protocol is supervised. The best evidence anchors are Shimizu et al. 2025, which RCT n=110 randomized; no statistically significant overall primary or secondary endpoint changes; male subgroup CD8+ high-SA-beta-gal signal only, and Guan et al. 2024, which 83 included articles; 78 animal studies and 5 human studies; human dietary-senotherapeutic evidence limited with unclear risk of bias. Senolytics are compounds intended to clear senescent cells. That makes the intervention most useful when the reader wants the studied outcome, accepts the evidence limits, and can track whether the response shows up.
✅ Best for: Adults over 50 with measurable signs of age-related decline, chronic low-grade inflammation, reduced physical function, fibrotic conditions, metabolic disease, or high suspected senescent-cell burden. Biohackers who want to explore the senolytic mechanism without dasatinib's prescription-drug risk. People who understand that F+Q is a low-cost experiment, not a proven longevity therapy. Older users who can review CYP3A4 and anticoagulant interactions before a short dosing window. Patients considering D+Q only under clinician supervision, especially where early human pilots such as Justice 2019 or Hickson 2019 are relevant to their condition.
❌ Avoid if: You are under 40 with no signs of accelerated aging. You have active cancer or recent cancer history unless your oncologist explicitly clears it. You take warfarin, a direct oral anticoagulant, high-dose aspirin, or high-risk CYP3A4-dependent medications. You are pregnant, breastfeeding, preparing for surgery, dealing with severe liver or kidney disease, or expecting Phase 3-level proof. Avoid D+Q without medical supervision. No FDA approval, Cochrane synthesis, USPSTF recommendation, NICE endorsement, or IPF society guideline supports senolytics for healthy aging as of the 2026-05-03 audit.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Longevity / Lifespan: 6.8/10
Score: 6.8/10Senolytics scores 6.8/10 for longevity, with the best signal coming from Shimizu et al. 2025. Yousefzadeh 2018 supports fisetin lifespan and healthspan effects in mice; Farr 2024 tempers human extrapolation for D+Q. The score stays bounded because Senolytics evidence for longevity can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Healthspan: 7.0/10
Score: 7.0/10For healthspan, Senolytics lands at 7.0/10 because Guan et al. 2024 supports the core mechanism. Xu 2018 found D+Q improved physical function and post-treatment survival in old mice; human healthspan outcomes remain unproven. The score stays bounded because Senolytics evidence for healthspan can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Cellular Senescence: 8.2/10
Score: 8.2/10The cellular senescence use case earns 8.2/10 for Senolytics, anchored by Silva et al. 2024. Direct mechanism: Zhu 2015 identified senescent-cell anti-apoptotic pathway vulnerabilities; Zhu 2017 identified fisetin as senolytic in selected cell types. The score stays bounded because Senolytics evidence for cellular senescence can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Anti-Inflammatory: 7.0/10
Score: 7.0/10Evidence puts Senolytics at 7.0/10 for anti inflammatory, mainly through Farr et al. 2024. SASP suppression is central to the mechanism; Hickson 2019 supports marker movement for D+Q but is preliminary and corrected-conclusion-sensitive. The score stays bounded because Senolytics evidence for anti inflammatory can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Immune Function: 6.0/10
Score: 6.0/10A cautious immune function score of 6.0/10 fits Senolytics, with Baker et al. 2011 preventing a stronger claim. Shimizu 2025 found no overall primary immune endpoint benefit for APE, but did report a male subgroup CD8+ senescence-marker signal. The score stays bounded because Senolytics evidence for immune function can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Bone / Joint Health: 6.5/10
Score: 6.5/10A 6.5/10 bone joint rating fits Senolytics, since Hickson et al. 2019 points to a real but bounded effect. Bone rationale is strong preclinically, but Farr 2024 found D+Q did not improve the primary bone resorption endpoint overall. The score stays bounded because Senolytics evidence for bone joint can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Antioxidant / Oxidative Stress: 6.5/10
Score: 6.5/10Antioxidant is a 6.5/10 fit for Senolytics, based on the evidence summarized in Lee et al. 2024. Both fisetin and quercetin are flavonoid polyphenols; Guan 2024 found dietary senotherapeutic evidence is mostly animal-level and human evidence remains limited. The score stays bounded because Senolytics evidence for antioxidant can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Stem Cell Support: 6.5/10
Score: 6.5/10The use-case math gives Senolytics 6.5/10 for stem cell, guided by Guan et al. 2024. Chang 2016 showed ABT263 cleared senescent cells and rejuvenated aged mouse hematopoietic and muscle stem-cell compartments; F+Q translation is unknown. The score stays bounded because Senolytics evidence for stem cell can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Respiratory: 6.3/10
Score: 6.3/10The evidence-weighted call is 6.3/10 for Senolytics in respiratory, led by Yousefzadeh et al. 2018. Justice 2019 IPF pilot found feasibility and physical-function signals with D+Q, not F+Q, with no control group. The score stays bounded because Senolytics evidence for respiratory can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Cardiovascular: 6.2/10
Score: 6.2/10Senolytics reaches 6.2/10 for cardiovascular when the goal matches the population in Chaib et al. 2022. Senescent endothelial-cell clearance supports vascular function in preclinical models; human cardiovascular outcome data for F+Q is absent. The score stays bounded because Senolytics evidence for cardiovascular can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Skin / Beauty: 6.2/10
Score: 6.2/10Senolytics is a 6.2/10 option for skin beauty, especially where the context resembles Chang et al. 2016. Senescent fibroblast clearance fits skin-aging theory, but no human F+Q skin-aging outcome trial was verified in the audit. The score stays bounded because Senolytics evidence for skin beauty can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Kidney Function: 6.0/10
Score: 6.0/10For readers tracking kidney function, Senolytics deserves 6.0/10 because Justice et al. 2019 gives the strongest anchor. Hickson 2019 reported D+Q senescence-marker reductions in diabetic kidney disease, but it was small, preliminary, and later corrected. The score stays bounded because Senolytics evidence for kidney function can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Neuroprotection: 6.0/10
Score: 6.0/10The strongest neuroprotection argument for Senolytics is worth 6.0/10, with Zhu et al. 2017 as the anchor. Senescent glial-cell clearance remains a research target; Chaib 2022 frames neurodegeneration as promising but clinically early. The score stays bounded because Senolytics evidence for neuroprotection can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Metabolic Health: 6.0/10
Score: 6.0/10In metabolic health, Senolytics rates 6.0/10 because Baker et al. 2016 supports selective use. Senescent preadipocyte and adipose-inflammation mechanisms are plausible from preclinical D+Q work, but F+Q human metabolic endpoints are not proven. The score stays bounded because Senolytics evidence for metabolic health can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Telomere / DNA Repair: 5.8/10
Score: 5.8/10Senolytics earns 5.8/10 in telomere dna because Shimizu et al. 2025 supports the main pathway. Lee 2024 found concerning first-generation clock and telomere signals with DQ, while second and third-generation clocks were not significant. The score stays bounded because Senolytics evidence for telomere dna can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Recovery / Repair: 5.8/10
Score: 5.8/10The recovery repair evidence puts Senolytics at 5.8/10, helped by Lee et al. 2024. Tissue remodeling depends on balanced senescence and clearance; Chaib 2022 stresses clinical translation is still early. The score stays bounded because Senolytics evidence for recovery repair can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Autophagy: 5.5/10
Score: 5.5/10The practical autophagy read is 5.5/10 for Senolytics, with Gonzales et al. 2023 setting the ceiling. Indirect via cellular renewal after senescent-cell clearance; no direct human F+Q autophagy-marker trial was verified in the audit. The score stays bounded because Senolytics evidence for autophagy can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Cognition / Focus: 5.5/10
Score: 5.5/10Senolytics has a 5.5/10 cognition focus case because Xu et al. 2018 supports a plausible benefit. Gonzales 2023 was a 5-person Alzheimer's feasibility trial of D+Q; it supports CNS-penetrance questions, not cognitive efficacy. The score stays bounded because Senolytics evidence for cognition focus can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Mitochondrial: 5.5/10
Score: 5.5/10The mitochondrial score sits at 5.5/10 for Senolytics, reflecting the evidence in Zhu et al. 2015. Senescent cells often carry mitochondrial dysfunction; clearing them may improve tissue pool quality, but this is indirect for F+Q. The score stays bounded because Senolytics evidence for mitochondrial can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Injury Recovery: 5.5/10
Score: 5.5/10Senolytics belongs at 5.5/10 for injury recovery, with Farr et al. 2024 supporting the practical upside. Senescent cells can impair repair but also assist wound healing in specific contexts, making timing critical and human evidence insufficient. The score stays bounded because Senolytics evidence for injury recovery can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Methylation Support: 5.5/10
Score: 5.5/10A 5.5/10 rating for methylation is fair for Senolytics, because Gonzales et al. 2023 supports limited benefit. Lee 2024 found mixed methylation-clock effects, including first-generation clock acceleration signals after DQ. The score stays bounded because Senolytics evidence for methylation can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Energy / Fatigue: 5.5/10
Score: 5.5/10Senolytics gets 5.5/10 for energy, with Chaib et al. 2022 giving the cleanest evidence anchor. Reduced SASP inflammation may improve subjective energy in older or inflamed users, but human F+Q energy outcomes remain untested. The score stays bounded because Senolytics evidence for energy can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Hormonal / Endocrine: 5.0/10
Score: 5.0/10For hormonal, the 5.0/10 score reflects how Senolytics performs in Silva et al. 2024. Any endocrine benefit is indirect through metabolic and inflammatory-cell senescence; no verified human hormonal F+Q endpoint exists. The score stays bounded because Senolytics evidence for hormonal can depend on age, disease context, drug interactions, and whether the protocol is supervised. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
| Use Case | Score | Summary |
|---|---|---|
| ⚖️ Libido / Sexual Health | 4.8 | Potential benefit is indirect through metabolic and hormonal improvements; no verified libido trial exists for F+Q or D+Q. |
Frequently Asked Questions
What are senolytics and how do they work?
Senolytics are compounds that selectively push some senescent cells into apoptosis by weakening survival pathways such as BCL-2, BCL-xL, PI3K, and AKT. Zhu 2015 identified these senescent-cell anti-apoptotic pathways as drug targets. The goal is to lower SASP, the inflammatory signal cloud secreted by persistent senescent cells. The idea is elegant, but human proof for OTC F+Q is still missing, especially for healthy longevity users. That is why age and disease burden matter so much.
Fisetin + quercetin vs dasatinib + quercetin: which is better?
D+Q has stronger human pilot evidence; F+Q has the better consumer safety and access profile. Justice 2019 and Hickson 2019 used prescription D+Q in small human pilots. F+Q relies mostly on fisetin mouse and cell evidence from Yousefzadeh 2018. Dasatinib adds serious prescription-drug risks, so D+Q belongs under clinician supervision, not casual experimentation. For most readers, F+Q is the safer first experiment.
Does fisetin actually work as a senolytic in humans?
Not yet as a proven clinical intervention. Yousefzadeh 2018 showed fisetin reduced senescence markers and extended health and lifespan in mice, with supportive human adipose explant data. But that is not a human outcome trial. AFFIRM-LITE, COVID-FISETIN, and STOP-Sepsis are the kinds of trials needed to close the gap.
How do I run a senolytic protocol?
The common OTC protocol is fisetin 1,000-2,000 mg plus quercetin 1,000-1,250 mg for 2 consecutive days, repeated quarterly. Take with a fat-containing meal. Review medications first because quercetin inhibits CYP3A4, and both compounds can matter around anticoagulants or bleeding risk. Daily dosing misses the point. Senolytics are usually treated as hit-and-run pulses because the target cells take time to reaccumulate.
Are senolytics safe?
F+Q is usually well tolerated, but the safety story is mostly interaction-driven. Expect occasional GI discomfort at high fisetin doses. The bigger concerns are anticoagulants, CYP3A4-metabolized drugs, active cancer, pregnancy, severe kidney or liver disease, and perioperative timing. D+Q is different: dasatinib is an oncology drug with risks including myelosuppression, bleeding, fluid retention, pulmonary arterial hypertension, QT prolongation, and hepatotoxicity.
When should I start taking senolytics?
Age 50+ is the more defensible starting zone because senescent-cell burden rises with age and chronic disease. Yousefzadeh 2018 treated mice late in life, which matches the idea that higher burden creates more upside. Younger healthy adults probably have little to clear and more uncertainty. Chronic disease, obesity, fibrosis, chemotherapy exposure, or accelerated aging may shift the decision earlier, but that should be individualized with medication review. A clinician can help sort that risk.
Who should avoid senolytics?
Avoid senolytics if you have active cancer or recent cancer history unless your oncologist clears it. Senescence can be tumor-suppressive. Also avoid unsupervised use with warfarin, direct oral anticoagulants, high-dose aspirin, strong CYP3A4-dependent medications, pregnancy, breastfeeding, severe renal disease, severe liver disease, or upcoming surgery. Young healthy adults under 40 with no accelerated-aging signal are a poor risk-reward fit.
Why is the BioHarmony score only 6.8 if the mouse data looks strong?
The score is capped by translation risk. The mouse data is strong, but F+Q has no published human senolytic efficacy trial. Farr 2024 found a null primary endpoint in a D+Q bone RCT, and Shimizu 2025 was mostly null overall for a different senolytic botanical. No FDA, Cochrane, USPSTF, NICE, or IPF society endorsement supports consumer senolytic use for healthy aging.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions changed | New score |
|---|---|---|
| AFFIRM-LITE publishes positive fisetin senolytic data | Evidence 1.8 to 3.0; Efficacy 2.5 to 3.2 | 7.0 / 10 💪 Strong recommend |
| D+Q Phase 3 RCT validates senolytic class in n>200 adults | Evidence 1.8 to 2.8; Efficacy 2.5 to 3.0 | 6.8 / 10 💪 Strong recommend |
| CYP3A4 interaction causes serious harm in a combination user | Safety 1.5 to 2.5 | 5.8 / 10 👍 Worth trying |
| Yousefzadeh mouse lifespan extension fails to replicate | Efficacy 2.5 to 1.8 | 5.7 / 10 👍 Worth trying |
| 5-year follow-up data confirms zero serious safety issues in 200+ F+Q users | Safety 1.5 to 1.2 | 6.4 / 10 💪 Strong recommend |
| Epigenetic-clock acceleration signal is confirmed in larger controlled trials | Safety 1.5 to 2.5; Efficacy 2.5 to 2.0 | 5.3 / 10 👍 Worth trying |
Key Evidence Sources
- Shimizu et al. 2025 - Preliminary Data on the Senolytic Effects of Agrimonia pilosa Ledeb. Extract Containing Agrimols for Immunosenescence in Middle-Aged Humans, Nutrients. RCT n=110 randomized; no statistically significant overall primary or secondary endpoint changes; male subgroup CD8+ high-SA-beta-gal signal only
- Guan et al. 2024 - Therapeutic effect of dietary ingredients on cellular senescence in animals and humans: systematic review, Ageing Research Reviews. 83 included articles; 78 animal studies and 5 human studies; human dietary-senotherapeutic evidence limited with unclear risk of bias
- Silva et al. 2024 - STOP-Sepsis fisetin protocol, Trials. Protocol only; planned n=220 older sepsis patients; no efficacy results available
- Farr et al. 2024 - Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women, Nature Medicine. Phase 2 RCT n=60; D+Q did not improve the primary CTx endpoint overall; no serious adverse events reported
- Lee et al. 2024 - Effects of Dasatinib, Quercetin, and Fisetin on DNA methylation clocks, Aging. Longitudinal pilot n=19 per phase; DQ increased first-generation clock acceleration signals; second and third-generation clock effects were not significant
- Gonzales et al. 2023 - Senolytic therapy in mild Alzheimer's disease: phase 1 feasibility trial, Nature Medicine. Open-label feasibility trial; 5 participants completed 12 weeks; evaluates CNS penetrance, safety, and feasibility, not efficacy
- Chaib et al. 2022 - Cellular senescence and senolytics: the path to the clinic, Nature Medicine. Clinical translation review; stresses that senolytics should not be endorsed for OTC disease prevention or treatment before rigorous clinical trials
- Hickson et al. 2019 - Senolytics decrease senescent cells in humans: preliminary D+Q diabetic kidney disease report, EBioMedicine. Small preliminary human trial n=14; reported senescence-marker changes with later corrigendum requiring caution around exact numerical claims
- Justice et al. 2019 - Senolytics in idiopathic pulmonary fibrosis: first-in-human open-label pilot, EBioMedicine. Open-label IPF pilot n=14; D+Q feasible with physical-function signals and no control group
- Yousefzadeh et al. 2018 - Fisetin is a senotherapeutic that extends health and lifespan, EBioMedicine. Fisetin reduced senescence markers in mice and human adipose tissue explants; extended mouse health and lifespan; no human clinical outcome proof
- Xu et al. 2018 - Senolytics improve physical function and increase lifespan in old age, Nature Medicine. D+Q preclinical proof-of-concept; improved physical function and post-treatment survival in old mice
- Zhu et al. 2017 - New agents that target senescent cells: fisetin and BCL-XL inhibitors, Aging. Identified fisetin as senolytic in selected senescent human endothelial cells, with cell-type specificity
- Baker et al. 2016 - Naturally occurring p16Ink4a-positive cells shorten healthy lifespan, Nature. Genetic senescent-cell clearance extended median mouse lifespan and delayed organ deterioration without apparent side effects
- Chang et al. 2016 - Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice, Nature Medicine. ABT263 cleared senescent cells and rejuvenated aged mouse hematopoietic and muscle stem-cell compartments
- Zhu et al. 2015 - The Achilles' heel of senescent cells: from transcriptome to senolytic drugs, Aging Cell. Foundational SCAP-targeting paper that identified senescent-cell survival pathway vulnerabilities
- Baker et al. 2011 - Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders, Nature. Foundational INK-ATTAC mouse experiment showing senescent-cell clearance delayed age-associated phenotypes
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Low
Citations: Shimizu 2025, Guan 2024, Silva 2024, Farr 2024, Lee 2024, Gonzales 2023, Hickson 2019, Justice 2019, Yousefzadeh 2018, Xu 2018
Pre-RCT-Era Pharmacology and Use
Confidence: Medium
Citations: Hayflick 1961, Baker 2011, Zhu 2015, Baker 2016, Yousefzadeh 2018
Traditional Medicine Systems
Confidence: Low
Holistic Evidence for Senolytics
All lenses point in the same broad direction but with different strength. Modern science gives the cleanest mechanism and early human pilots, scientific history shows senescent-cell clearance repeatedly works in mice, and traditional food use supports general flavonoid exposure. They do not converge on a proven anti-aging protocol. The honest synthesis: senolytics are one of the more interesting longevity mechanisms, but F+Q is still an experiment for older or higher-burden users, not a validated maintenance supplement for healthy young adults.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- hs-CRP Baseline (pre-protocol) Post | Expected Down
- WBC During | Expected Stable
- Platelets During | Expected Stable
- ALT During | Expected Stable
- AST During | Expected Stable
Pulse Dimensions to Watch
- Body During | Expected Watch | Primary
- Energy During | Expected Watch | Secondary
- Calm During | Expected Stable | Tertiary
Subjective Signals (Daily Voice Card)
- Post-Dose Fatigue Scale 1-5 | During | Expected Watch
- Joint Comfort Scale 1-5 | During | Expected Up
- GI Comfort Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Jaundice or yellowing of eyes
- Dark urine with right upper quadrant pain
- ALT or AST above 3x baseline
- Easy bruising or infection symptoms
Other interventions for Longevity
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.785 − 0.593 = 1.192
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (1.192 / 5) × 5 = 6.2 / 10
Further learning
8 Best Senolytic Supplements to Rid Your “Zombie” Cells & Extend Healthspan
Senolytics help rid the body of defective cells and appear to slow the aging process.
Latest Insights from 53+ Longevity Experts
What are the hallmarks of aging? How exactly does our diet relate to our longevity and age-related issues? Chris Burres gives us the inside…
